Precigen director sells 185K shares at $7.44

Rhea-AI Filing Summary

PRECIGEN, INC. (PGEN) director Jeffrey B. Kindler reported selling 185,000 shares of common stock on 2026-08-26 in an open market or private transaction. The weighted average sale price was $7.44 per share, with individual trades executed between $7.38 and $7.59. Following this sale, Kindler directly holds 17,100 shares of Precigen common stock.

Insider Trade Summary

Net Seller: 185,000 shares

Net Sell 1 txn

Insider KINDLER JEFFREY B

Role Director

Sold 185,000 shs ($1.38M)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	185,000	$7.44	$1.38M

Holdings After Transaction: Common Stock — 17,100 shares (Direct)

Footnotes (1)

1. F1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.38 to $7.59, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.

Key Figures

Shares sold: 185,000 shares Weighted average sale price: $7.44 per share Sale price range: $7.38–$7.59 per share +1 more

4 metrics

Shares sold 185,000 shares Common Stock sold on 2026-08-26

Weighted average sale price $7.44 per share Sale of 185,000 Common Stock shares on 2026-08-26

Sale price range $7.38–$7.59 per share Individual trades within the 185,000-share sale

Shares owned after transaction 17,100 shares Direct holdings of Jeffrey B. Kindler after the 2026-08-26 sale

Key Terms

weighted average price, open market or private transaction, beneficial ownership

3 terms

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open market or private transaction financial

"transaction_code_description": "Sale in open market or private transaction"

beneficial ownership financial

"full information regarding the number of shares sold at each separate price"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did PGEN director Jeffrey B. Kindler report?

Jeffrey B. Kindler reported selling 185,000 shares of PRECIGEN, INC. common stock on 2026-08-26 in an open market or private transaction at a weighted average price of $7.44 per share, with prices ranging from $7.38 to $7.59.

At what price did Jeffrey B. Kindler sell PGEN shares?

The reported weighted average sale price was $7.44 per PGEN share. According to the disclosure, the 185,000 shares were sold in multiple transactions at prices ranging from $7.38 to $7.59 per share.

How many PGEN shares does Jeffrey B. Kindler hold after this sale?

After the 185,000-share sale, Jeffrey B. Kindler directly holds 17,100 shares of PRECIGEN, INC. common stock, as reported in the Form 4 filing for the transaction dated 2026-08-26.

Was the reported PGEN stock sale by Jeffrey B. Kindler a single trade?

No. The filing states the 185,000 shares of PGEN common stock were sold in multiple transactions on 2026-08-26 at prices ranging from $7.38 to $7.59, with a reported weighted average price of $7.44 per share.

Does the Form 4 indicate a Rule 10b5-1 trading plan for the PGEN sale?

No. The filing’s Rule 10b5-1 checkbox is not checked, and the footnote does not mention any Rule 10b5-1 or pre-arranged trading plan for this 185,000-share sale of PRECIGEN, INC. stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/28/2026 - 08:39 PM EDT Accepted by SEC EDGAR 08/28/2026 - 08:39 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KINDLER JEFFREY B

(Last) (First) (Middle)

20374 SENECA MEADOWS PARKWAY

(Street)

GERMANTOWN MARYLAND 20876

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PRECIGEN, INC. [ PGEN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/26/2026		S		185,000	D	$7.44(1)	17,100	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.38 to $7.59, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.

	/s/ Jeffrey B. Kindler, by Donald P. Lehr, as attorney-in-fact	08/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)